WEDEMEYER, H., A. S. DUBERG, M. BUTI, W. M. ROSENBERG, S. FRANKOVA, G. ESMAT, N. ÖRMECI, H. VAN VLIERBERGHE, M. GSCHWANTLER, U. AKARCA, S. ALEMAN, I. BALIK, T. BERG, F. BIHL, M. BILODEAU, A. J. BLASCO, C. E. Brandão MELLO, P. BRUGGMANN, F. CALINAS, J. L. CALLEJA, H. CHEINQUER, P. B. CHRISTENSEN, M. CLAUSEN, H. S. M. COELHO, M. CORNBERG, M. E. CRAMP, G. J. DORE, W. DOSS, M. H. EL-SAYED, G. ERGÖR, C. ESTES, K. FALCONER, J. FÉLIX, M. L. G. FERRAZ, P. R. FERREIRA, J. GARCÍA-SAMANIEGO, J. GERSTOFT, J. A. GIRIA, F. L. Jr. GONÇALES, M. Guimarães PESSÔA, C. HÉZODE, S. J. HINDMAN, H. HOFER, Petr HUSA, R. IDILMAN, M. KÅBERG, K. D. E. KAITA, A. KAUTZ, S. KAYMAKOGLU, M. KRAJDEN, H. KRARUP, W. LALEMAN, D. LAVANCHY, P. LÁZARO, R. T. MARINHO, P. MAROTTA, S. MAUSS, M. C. Mendes CORREA, C. MORENO, B. MÜLLHAUPT, R. P. MYERS, V. NEMECEK, A. L. H. ØVREHUS, J. PARKES, K. M. PELTEKIAN, A. RAMJI, H. RAZAVI, N. REIS, S. K. ROBERTS, F. ROUDOT-THORAVAL, S. D. RYDER, R. SARMENTO-CASTRO, C. SARRAZIN, D. SEMELA, M. SHERMAN, G. E. SHIHA, J. SPERL, P. STÄRKEL, R. E. STAUBER, A. J. THOMPSON, P. URBANEK, P. Van DAMME, I. van THIEL, D. VANDIJCK, W. VOGEL, I. WAKED, N. WEIS, J. WIEGAND, A. YOSRY, A. ZEKRY, F. NEGRO, W. SIEVERT and E. GOWER. Strategies to manage hepatitis C virus (HCV) disease burden. JOURNAL OF VIRAL HEPATITIS. HOBOKEN: WILEY-BLACKWELL, 2014, vol. 21, Supplement 1, p. 60-89. ISSN 1352-0504. Available from: https://dx.doi.org/10.1111/jvh.12249.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Strategies to manage hepatitis C virus (HCV) disease burden
Authors WEDEMEYER, H. (276 Germany), A. S. DUBERG (752 Sweden), M. BUTI (724 Spain), W. M. ROSENBERG (826 United Kingdom of Great Britain and Northern Ireland), S. FRANKOVA (203 Czech Republic), G. ESMAT (818 Egypt), N. ÖRMECI (792 Turkey), H. VAN VLIERBERGHE (56 Belgium), M. GSCHWANTLER (40 Austria), U. AKARCA (792 Turkey), S. ALEMAN (752 Sweden), I. BALIK (792 Turkey), T. BERG (276 Germany), F. BIHL (756 Switzerland), M. BILODEAU (124 Canada), A. J. BLASCO (724 Spain), C. E. Brandão MELLO (76 Brazil), P. BRUGGMANN (756 Switzerland), F. CALINAS (620 Portugal), J. L. CALLEJA (724 Spain), H. CHEINQUER (76 Brazil), P. B. CHRISTENSEN (208 Denmark), M. CLAUSEN (208 Denmark), H. S. M. COELHO (76 Brazil), M. CORNBERG (276 Germany), M. E. CRAMP (826 United Kingdom of Great Britain and Northern Ireland), G. J. DORE (36 Australia), W. DOSS (818 Egypt), M. H. EL-SAYED (818 Egypt), G. ERGÖR (792 Turkey), C. ESTES (840 United States of America), K. FALCONER (752 Sweden), J. FÉLIX (620 Portugal), M. L. G. FERRAZ (76 Brazil), P. R. FERREIRA (76 Brazil), J. GARCÍA-SAMANIEGO (724 Spain), J. GERSTOFT (208 Denmark), J. A. GIRIA (620 Portugal), F. L. Jr. GONÇALES (76 Brazil), M. Guimarães PESSÔA (76 Brazil), C. HÉZODE (250 France), S. J. HINDMAN (840 United States of America), H. HOFER (40 Austria), Petr HUSA (203 Czech Republic, guarantor, belonging to the institution), R. IDILMAN (792 Turkey), M. KÅBERG (752 Sweden), K. D. E. KAITA (124 Canada), A. KAUTZ (56 Belgium), S. KAYMAKOGLU (792 Turkey), M. KRAJDEN (124 Canada), H. KRARUP (208 Denmark), W. LALEMAN (56 Belgium), D. LAVANCHY (756 Switzerland), P. LÁZARO (724 Spain), R. T. MARINHO (620 Portugal), P. MAROTTA (124 Canada), S. MAUSS (276 Germany), M. C. Mendes CORREA (76 Brazil), C. MORENO (56 Belgium), B. MÜLLHAUPT (756 Switzerland), R. P. MYERS (124 Canada), V. NEMECEK (203 Czech Republic), A. L. H. ØVREHUS (208 Denmark), J. PARKES (826 United Kingdom of Great Britain and Northern Ireland), K. M. PELTEKIAN (124 Canada), A. RAMJI (124 Canada), H. RAZAVI (840 United States of America), N. REIS (620 Portugal), S. K. ROBERTS (36 Australia), F. ROUDOT-THORAVAL (250 France), S. D. RYDER (826 United Kingdom of Great Britain and Northern Ireland), R. SARMENTO-CASTRO (620 Portugal), C. SARRAZIN (276 Germany), D. SEMELA (756 Switzerland), M. SHERMAN (124 Canada), G. E. SHIHA (818 Egypt), J. SPERL (203 Czech Republic), P. STÄRKEL (56 Belgium), R. E. STAUBER (40 Austria), A. J. THOMPSON (40 Austria), P. URBANEK (203 Czech Republic), P. Van DAMME (56 Belgium), I. van THIEL (56 Belgium), D. VANDIJCK (56 Belgium), W. VOGEL (40 Austria), I. WAKED (818 Egypt), N. WEIS (208 Denmark), J. WIEGAND (276 Germany), A. YOSRY (818 Egypt), A. ZEKRY (36 Australia), F. NEGRO (756 Switzerland), W. SIEVERT (36 Australia) and E. GOWER (840 United States of America).
Edition JOURNAL OF VIRAL HEPATITIS, HOBOKEN, WILEY-BLACKWELL, 2014, 1352-0504.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30300 3.3 Health sciences
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 3.909
RIV identification code RIV/00216224:14110/14:00075456
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1111/jvh.12249
UT WoS 000333893200004
Keywords in English diagnosis; epidemiology; HCV; mortality; treatment; scenarios; prevalence; incidence; hepatitis C; disease burden
Tags EL OK
Tags International impact, Reviewed
Changed by Changed by: Ing. Mgr. Věra Pospíšilíková, učo 9005. Changed: 13/5/2014 10:36.
Abstract
The number of hepatitis C virus (HCV) infections is projected to decline while those with advanced liver disease will increase. A modeling approach was used to forecast two treatment scenarios: (i) the impact of increased treatment efficacy while keeping the number of treated patients constant and (ii) increasing efficacy and treatment rate. This analysis suggests that successful diagnosis and treatment of a small proportion of patients can contribute significantly to the reduction of disease burden in the countries studied. The largest reduction in HCV-related morbidity and mortality occurs when increased treatment is combined with higher efficacy therapies, generally in combination with increased diagnosis. With a treatment rate of approximately 10%, this analysis suggests it is possible to achieve elimination of HCV (defined as a >90% decline in total infections by 2030). However, for most countries presented, this will require a 3-5 fold increase in diagnosis and/or treatment. Thus, building the public health and clinical provider capacity for improved diagnosis and treatment will be critical.
PrintDisplayed: 30/7/2024 03:30